Compare Marvell Technology Inc (MRVL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Summit Therapeutics Inc — how do they compare? Marvell Technology Inc trades at $212.5 (market cap $171.11B), while Summit Therapeutics Inc trades at $14.57 (market cap $10.48B). The key difference: Marvell Technology Inc is far larger — about 16.3× Summit Therapeutics Inc's market cap, and Marvell Technology Inc pays a 0.12% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MRVL | SMMT | |
|---|---|---|
Market Cap | $171.11B | $10.48B |
Sector | Technology | Health |
52-Week High | $316.43 | $29.32 |
52-Week Low | $62.31 | $13.05 |
Enterprise Value | $172.55B | $9.90B |
Dividend Yield | 0.12% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
